The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (8 analysts) rates it buy, with a mean price target of $86.
National Health Investors, Inc. NHI
Clears the common standardAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · National Health Investors, Inc.
read at $79.61
National Health Investors, Inc. holds its Markup at $79.61.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | Elevated stress, defensive posture warranted, held for 497 days |
| Price | $79.61 |
| Valuation | 25.68 trailing · 23.08 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.54 |
The opportunity · what the numbers say it is worth
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the Street see limited upside at this price.
| Revenue growth | -2.60% |
| Profit margin | 36.60% |
| Debt to equity | 97.57 |
| Analyst consensus | Buy · 8 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
It depends which standard you follow. There are two widely recognised ways to check whether a company is suitable for a Muslim investor, and on this company they disagree. Here is how it did on each:
Used by most halal investing apps ✗ DOES NOT PASS
The one Titan applies ✓ PASSES
Why the two disagree. They fall out over one thing only: the company’s debt. Our stricter standard measures that debt against what the company owns, and it works out too high to pass. The common standard measures the same debt against what the company is worth on the stock market, where it works out low enough to pass. Every other check, the two agree on. So in practice, most halal apps would treat this as fine to hold, while our stricter view would not — and which line you follow is between you and your scholar.
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Against market value it is 39.5%, under the 30% line the market-value standard uses — so that standard clears it. Divergent
- Interest-bearing cash Interest-bearing cash and securities are of assets, above the one-third limit. Fail
- Receivables Money owed to the company is of assets, above the 49% limit. Fail
- Revenue purity Only 0.0% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Senior Housing REITs Trade At A Premium Price
Picture a landlord collecting steady rents from care homes and clinics while the population ages. National Health Investors fits that picture exactly, owning a portfolio of senior housing and medical facilities through sale-leasebacks and mortgages. The business clears a 37 percent profit margin and passes our ethical screen without issue, yet revenue is already falling 3 percent and the shares sit 15 percent above our fair value.
We pass because the numbers do not justify the price. A 23.1 times forward earnings multiple on a company growing backwards and earning a modest 10 percent return on equity leaves little room for error. Analyst targets hover near the current level, but that consensus simply reflects the same stretched valuation rather than any fresh growth catalyst.
Interest rate moves and rising care-home costs remain the clearest risks, both of which can squeeze REIT cash flows quickly. Even a stable operator can look expensive when the multiple already prices in perfection. Analysis, not advice.
| Forward P/E | 23.1x a premium valuation |
| Trailing P/E | 25.7x a premium valuation |
| Revenue growth | -2.6% revenue is shrinking |
| Profit margin | 36.6% highly profitable on every dollar of sales |
| Return on equity | 9.9% a modest return on shareholder capital |
| Debt to equity | 0.98 moderate, manageable leverage |
| Current ratio | 0.60 below 1 — short-term bills exceed liquid assets |
| Beta | 0.54 steadier than the market |
| Market cap | $3.9B |
| Employees | 32 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in NHI's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
NHI trades on the NYSE. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $73.43 | -1.8% | · | $982 | -1.8% |
| 2 months | $86.48 | -16.6% | · | $834 | -16.6% |
| 3 months | $84.56 | -14.7% | $0.92 | $864 | -13.6% |
| 6 months | $74.13 | -2.7% | $1.84 | $998 | -0.2% |
| 1 year | $68.49 | +5.3% | $3.66 | $1,107 | +10.7% |
| 2 years | $58.56 | +23.2% | $7.26 | $1,356 | +35.6% |
| 3 years | $44.85 | +60.8% | $10.86 | $1,850 | +85.0% |
| 5 years | $49.82 | +44.8% | $18.06 | $1,810 | +81.0% |
Historical returns from market close data. Past performance does not guarantee future results.